Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Yes, recent research and clinical trials have confirmed that Alzheimer’s disease progression can be slowed—a finding that marks a significant shift in how we approach dementia care. Two FDA-approved medications, lecanemab and donanemab, have demonstrated the ability to reduce cognitive decline in people with early-stage Alzheimer’s disease, offering measurable delays in symptom progression and functional decline. Beyond medications, emerging therapies like non-invasive brain stimulation and sensory-based treatments are showing promise in clinical trials, with some demonstrating cognitive decline reduction rates as high as 44%.
This doesn’t mean a cure, and these treatments work best when started early—before significant cognitive damage has accumulated. But the consistent evidence across multiple treatment modalities suggests that the trajectory of Alzheimer’s disease is no longer inevitable. For families facing a diagnosis, this represents a genuine opportunity to extend the period of independence and cognitive function.
Table of Contents
- How Much Can Alzheimer’s Progression Actually Be Slowed?
- FDA-Approved Treatments That Slow Cognitive Decline
- Beyond Medications: Emerging Therapies and Breakthroughs
- How These Treatments Impact Daily Life and Independence
- Safety Concerns, Eligibility, and Who Should Consider These Treatments
- The Pipeline: What’s Coming Next
- Administration Advances and Practical Improvements
- Conclusion
How Much Can Alzheimer’s Progression Actually Be Slowed?
The question isn’t whether these treatments stop Alzheimer’s disease—they don’t. Instead, they measurably reduce the rate at which cognitive decline occurs. Lecanemab, approved by the FDA in January 2023, reduces cognitive decline at 18 months and shows continued benefits through 36 months of treatment. In clinical trials, participants receiving lecanemab performed better on standardized cognitive decline measures including the ADCOMS (Alzheimer’s Disease Composite Score), CDR-SB (Clinical Dementia Rating Scale), and ADAS-Cog 14 (Alzheimer’s Disease Assessment Scale) compared to those receiving a placebo.
Donanemab, approved more recently in July 2024, shows a different advantage: it reduces the risk of progression to the next stage of Alzheimer’s disease by 27% when initiated early. This distinction matters because it suggests these drugs may work through slightly different mechanisms, and individual responses can vary. For a person in the early cognitive impairment stage, a 27% reduction in progression risk means meaningful extra months or years before symptoms advance to moderate dementia. Both medications target amyloid, one of the hallmark proteins that accumulates in Alzheimer’s disease. Meta-analyses comparing these drugs to control groups show they consistently outperform placebo on multiple cognitive decline measures and actually reduce amyloid burden in the brain—addressing the underlying disease biology rather than just masking symptoms.
FDA-Approved Treatments That Slow Cognitive Decline
Lecanemab and donanemab represent the first wave of disease-modifying Alzheimer’s treatments to reach the market. Lecanemab, a monoclonal antibody, was the first to receive full FDA approval, and it may extend independence in daily living activities by approximately 10 months. This means a person treated with lecanemab might retain the ability to manage their finances, take medications independently, or engage in personal care for roughly 10 months longer than they would without treatment—a tangible benefit for both the person and their caregiving family. Donanemab, approved nine months later, appears slightly more potent in early data, potentially extending independence in daily activities by approximately 13 months. However, the trade-off is more complex: donanemab requires fewer infusions than lecanemab, which is administratively simpler, but the clinical trials were conducted differently, making direct one-to-one comparisons difficult.
Both drugs are administered intravenously, which requires regular hospital or clinic visits—a significant burden for families managing other aspects of care. A critical limitation that patients and families must understand: these medications work best when started very early in the disease process, ideally during mild cognitive impairment or early dementia stages, not moderate or advanced disease. Additionally, both drugs carry a significant safety risk that must be weighed carefully. Amyloid-Related Imaging Abnormalities (ARIA)—brain changes visible on MRI that can include microhemorrhages or microinfarcts—occur at a rate 4.35 times higher in people taking lecanemab or donanemab compared to control groups. While most ARIA cases are asymptomatic, they require regular monitoring with MRI scans and carry potential neurological risks that should be discussed thoroughly before starting treatment.
Beyond Medications: Emerging Therapies and Breakthroughs
The therapeutic landscape for Alzheimer’s disease is expanding well beyond traditional pharmacology. Non-invasive brain stimulation, developed and tested by companies like Sinaptica Therapeutics, showed remarkable results in Phase 2 trials completed in late 2024: cognitive decline slowed by 44% compared to control groups. This approach uses electrical stimulation to enhance neural activity in brain regions affected by Alzheimer’s disease, and it represents a fundamentally different mechanism than the amyloid-targeting drugs. The advantage is that it doesn’t carry the same ARIA risks, though it does require regular clinical sessions. Flickering light and sound therapy at 40 Hz frequency represents another entirely different approach gaining momentum.
Phase 3 trials are currently underway, and preliminary results suggest this sensory-based intervention can slow cognitive decline and even reduce brain volume loss in some patients. The mechanism is thought to involve the activation of microglia—brain immune cells that clear amyloid—through rhythmic sensory stimulation. For patients who prefer non-pharmacological approaches or cannot tolerate injectable medications, this therapy offers a potential alternative, though it’s not yet FDA-approved and long-term efficacy data is still being gathered. A significant limitation of these emerging therapies is their current availability and accessibility. Brain stimulation requires access to specialized centers, and flickering light therapy, while theoretically simple, is still experimental outside clinical trial settings. Most of these approaches also lack the long-term safety and efficacy data that 20+ years of Alzheimer’s research has generated for traditional medications.
How These Treatments Impact Daily Life and Independence
The practical value of slowing Alzheimer’s progression lies in what remains possible. When lecanemab extends independence in daily living activities by 10 months, that translates into 10 additional months during which a person can likely manage their own hygiene, prepare simple meals, pay bills, or engage in hobbies without constant supervision. For some families, this period of preserved independence means fewer care hours purchased, a later transition to assisted living, or more time for meaningful shared activities while the person is still capable of reciprocal interaction. Donanemab’s 13-month advantage means even more time in this functional window. However, there’s an important comparison to make: these extensions are measured from the point of treatment initiation.
If someone waits until cognitive decline is more advanced before starting treatment, they may miss the window where maximum benefit is achievable. The timing of diagnosis and treatment initiation—often complicated by the need for formal testing, specialist referrals, and health insurance approval—can significantly impact the practical benefit a person receives. The trade-off families face is also worth acknowledging honestly. These treatments require regular infusions every 2-4 weeks (lecanemab) or every 4 weeks after loading (donanemab), necessitating trips to medical facilities, time away from other responsibilities, and the physical burden of IV placement. For a person with anxiety about medical procedures or mobility limitations, this burden may be substantial. Additionally, both drugs require regular MRI monitoring to watch for ARIA, adding further medical appointments and costs to the treatment regimen.
Safety Concerns, Eligibility, and Who Should Consider These Treatments
Amyloid-Related Imaging Abnormalities represent the most significant safety concern with both lecanemab and donanemab. While ARIA occurs in control groups at baseline rates, its incidence increases substantially with treatment. Some ARIA events are asymptomatic and detected only through routine MRI screening; others cause headaches, confusion, or vision changes. In rare cases, ARIA can lead to serious complications including microhemorrhages or microinfarcts. This is not a reason to avoid these treatments for the right patient, but it is a reason for thorough informed consent and careful neurological monitoring.
People with certain risk factors carry higher ARIA risk and require closer monitoring or may not be candidates for these treatments. Notably, carriers of the APOE4 gene variant—which increases Alzheimer’s disease risk—show higher rates of ARIA with both medications. Individuals with existing cerebrovascular disease, uncontrolled hypertension, or blood clotting disorders may face elevated risks as well. This means the decision to start lecanemab or donanemab cannot be made generically; it requires careful evaluation by a neurologist or dementia specialist familiar with an individual’s complete medical history. Additionally, these medications are approved only for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease—not for asymptomatic people who simply carry amyloid pathology, and not for moderate or advanced dementia where the disease biology has progressed beyond what these drugs can effectively address. Starting treatment too late in the disease process may expose a person to safety risks without meaningful cognitive benefit.
The Pipeline: What’s Coming Next
The Alzheimer’s disease drug development landscape is remarkably active. Currently, 138 different drugs are in 182 clinical trials, indicating robust pipeline activity across the research world. Notably, 73% of these new drugs target underlying disease biology—not just symptom management—suggesting that the therapeutic strategy pioneered by lecanemab and donanemab is becoming the standard approach.
One particularly promising candidate is BIIB080, a tau-targeting therapy currently in development. Tau is the other hallmark protein of Alzheimer’s disease (alongside amyloid), and it’s closely linked to cognitive decline. A Phase 1b study with 46 participants showed dose-dependent reduction in tau pathology, and the drug received FDA fast-track designation in April 2025. If tau-targeting therapies prove effective, they could potentially be combined with amyloid-targeting drugs like lecanemab and donanemab, creating a multi-pronged attack on the disease’s underlying biology.
Administration Advances and Practical Improvements
A significant recent development addresses one of the main burdens of treatment: lecanemab is now available as a subcutaneous injection rather than requiring hospital-based IV infusions. This formulation is bioequivalent to the intravenous version—meaning it provides the same cognitive benefits—but can be administered in an office-based setting with a simple injection, similar to other common medications. This represents a major quality-of-life improvement for patients, reducing the frequency of medical facility visits and the need for professional IV placement.
These administration advances, though they may seem technical, have real implications for treatment adherence and patient experience. As more Alzheimer’s treatments become available, the route of administration matters as much as the efficacy. A person who might abandon treatment because of the burden of weekly IV infusions might remain compliant with a medication they can inject at home or receive in a quick office visit.
Conclusion
The evidence is now clear: Alzheimer’s disease progression can be slowed, and multiple pathways to achieving that slowing are either available or rapidly approaching clinical use. Lecanemab and donanemab represent proven, FDA-approved options that can extend the period of cognitive function and independence by months—a meaningful outcome for families navigating this disease.
Emerging therapies like brain stimulation and flickering light therapy offer alternatives with different risk-benefit profiles, and a robust pipeline of new drugs targeting different aspects of disease biology suggests that future patients will have more options, potentially allowing for personalized treatment selection based on individual risk factors and disease characteristics. For someone recently diagnosed with mild cognitive impairment or early dementia due to Alzheimer’s disease, the conversation with a neurologist should no longer be “there’s nothing we can do.” Instead, it can be “here are the options, here’s what they can realistically achieve, here are the risks we’ll monitor carefully, and here’s how we’ll support you through treatment.” That shift in the conversation reflects real progress in a disease that, until recently, offered no disease-modifying interventions whatsoever.
